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Abstract
Introduction:	Tubercular	pleural	effusion	is	the	second	most	common	extrapulmonary	form	of	tuberculosis	in	India.	Developing	
nations	like	India	face	several	health	challenges	and	with	limited	resources,	appropriate	planning	and	channelization	of	the	same	
is	the	need	of	the	hour.	
Material and methods:	The	objective	of	the	study	was	to	determine	the	role	of	cartridge-based	nucleic	acid	amplification	test	
(CBNAAT)	in	the	diagnosis	of	tubercular	pleural	effusion	(TPE)	and	also	to	study	if	any	association	exists	between	CBNAAT	and	
pleural	fluid	adenosine	deaminase	(ADA)	and	lymphocyte	counts.	Clinically	suspected	TPE,	 lymphocyte	predominant	(≥	70%)	
exudates	(according	to	the	Lights	criteria)	with	ADA	≥	40	U/L	and	microbiologically	confirmed	pulmonary	tuberculosis	patients	
with	a co-existent	pleural	effusion	were	included.	Pleural	fluid	CBNAAT	was	performed	on	all	the	samples.
Results: Out	of	a total	of	75	patients,	57	were	males	and	18	were	females.	A lymphocyte	predominance	of	≥	70%	was	seen	in	
73	subjects	(97%).	Mean	ADA	was	61.7	U/L	±	16.2	(SD).	Pleural	fluid	CBNAAT	was	positive	for	Mycobacterium tuberculosis	
(MTB)	in	24	patients	(32%).	Out	of	these	patients,	rifampicin	resistance	was	detected	in	2	individuals	(8.3%).	Sputum	smear	for	
acid	fast	bacilli	(AFB)	was	positive	in	3	(4%)	patients,	whereas	in	sputum	CBNAAT	MTB	was	detected	in	8	(10.6%)	persons.	
Association	between	pleural	fluid	ADA,	lymphocyte	count	and	CBNAAT	positivity	was	evaluated	by	Student	T-test.	There	was	
a significant	association	between	higher	ADA	levels	and	CBNAAT	(p	value	=	0.001).	
Conclusions:	Pleural	fluid	CBNAAT,	owing	to	its	low	sensitivity,	should	not	be	included	in	the	diagnostic	protocol	of	TPE	in	high	
prevalence	areas.	A high	ADA	≥	40	U/L	in	combination	with	Light’s	criteria	to	define	exudates,	with	lymphocyte	predominance	is	
sufficient	evidence	to	diagnose	TPE	and	initiate	anti-tubercular	therapy,	thereby	deferring	the	need	to	perform	an	invasive	pleural	
biopsy.	
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Introduction
Extrapulmonary tuberculosis accounts for 
about 25% of active TB cases, with increasing 
incidence in the immunocompromised and chil-
dren [1]. After PTB, peripheral lymphatic TB 
predominates (47.2%), followed by tubercular 
pleural effusion (35.1%) [1]. Difficult sampling 
and paucibacillary nature of the disease contri-
bute to the diagnostic challenges that physicians 
face. Gene Xpert Mycobacterium Tuberculosis/ 
/Rifampicin Assay (Xpert, Cepheid, Sunnyvale, 
CA, USA), a  fully automated cartridge-based 
nucleic acid amplification test has resulted in 
a paradigm shift in the management of tuber-
culosis. This is a rapid, semi-quantitative nucleic 
acid amplification test (NAAT) with a definite 
role in the diagnosis of pulmonary tuberculosis. 
However, its role as a “routine must do test” in 
the diagnosis of pleural effusions is still unclear. 
Definitive diagnosis of tubercular pleural effusion 
(TPE) still depends on demonstration of Myco-
bacterium tuberculosis or caseous granulomas in 
pleural biopsy. However, they are laborious, time-
consuming and insensitive, when done blindly, 
and hence require expertise. Very high specificity 
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of the pleural fluid cartridge-based nucleic acid 
amplification test (CBNAAT) makes it an excel-
lent rule in test despite its low sensitivity, since 
it obviates the need for an invasive procedure 
in at least one-fourth of patients with TPE [2]. 
However, we are of the opinion that in a country 
like India where the prevalence of tuberculosis 
is very high, channelizing the limited resources 
to diagnose pulmonary tuberculosis, which is 
more communicable is the need of the hour. We 
believe that a high adenosine deaminase (ADA) 
(> 40 U/L) combined with Light’s criteria to define 
exudates in a lymphocyte predominant effusion 
constitutes enough evidence to diagnose TPE and 
initiate anti-tubercular therapy (ATT). Pleural 
biopsies and pleural fluid CBNAAT may be re-
served for patients with a low ADA and those in 
whom an alternate diagnosis seems more likely. 
Materials and methods
The study was conducted in the Department 
of Pulmonary Medicine, SDS TRC and RGICD on 
75 patients with tubercular pleural effusion. Pa-
tient’s demographic and anthropometric data was 
collected. Functional status assessment was done 
using the Karnofsky score. Diagnostic thoracocen-
tesis was performed and pleural fluid was sent 
for biochemical, cytological and microbiological 
(smear for acid fast bacilli-AFB) analysis. 10 mL of 
pleural fluid was sent for CB-NAAT. All patients 
were started on anti-tubercular therapy and were 
followed up with a chest X-ray to document the 
response to ATT at an interval of two months till 
completion of their treatment. On a chest X-ray, 
pleural effusions were categorized into mild (less 
than one-third of the hemithorax), moderate 
(one-third to two-third of the hemithorax) and 
massive (more than two-thirds of the hemithorax). 
Two experienced pulmonologists with six years of 
experience each, reviewed the radiographs inde-
pendently and reached a decision on the final in-
terpretation by consensus. Ethical clearance was 
obtained from the institutional ethical committee. 
Descriptive and inferential statistical analysis 
was carried out. The results of continuous me-
asurements like age are presented on Mean SD 
(min-max) and Median (IQR). The outcomes of 
categorical measurements are presented as num-
bers and percentages (%). Student t test was done 
to determine the association between CBNAAT 
and pleural fluid ADA, lymphocyte count in-
dividually. A p value of < 0.05 was considered 
significant. The statistical software, namely SPSS 
18.0 was used for the analysis of the data.
Inclusion criteria
1.  Patients willing to give a written informed 
consent. 
2.  All patients aged > 18 with a history com-
patible with tuberculosis and radiological 
evidence of pleural effusion on a chest X-ray. 
3.  Exudates with lymphocyte predominance 
(70%) (exudates defined according to the 
Light’s criteria) with ADA ≥ 40 U/L.
4.  Sputum AFB positive patients or sputum 
CBNAAT positive patients with a co-existent 
pleural effusion.
Exclusion criteria
1.  Exudative pleural effusions with neutrophil 
predominance or lymphocyte predominant 
with ADA <40 U/L.
2.  Transudative pleural effusions.
3.  Unresolved pleural effusions at the end of 
six months of ATT.
Objectives
1. To determine the role of genexpert in the 
diagnosis of tubercular pleural effusion. 
2. To study the association between pleural fluid 
CBNAAT and pleural fluid ADA. 
3. To study the association between pleural 
fluid CBNAAT and pleural fluid lymphocyte 
counts (%).
Results 
A total of 75 patients were selected for the 
study, and all of them had a complete resolution 
of pleural effusion at the end of six months of 
ATT. There were 57 male and 18 female patients, 
with a mean age of 36 years ± 13 (SD). The mean 
body mass index (BMI) was 19.58kg/m2 ± 3.88 
(SD) which, as per the World Health Organiza-
tion (WHO) BMI recommendation for Asians was 
within the normal range [3]. The functional status 
of the patients was assessed using the Karnofsky 
score and the mean score was 83.64 ± 10.3 (SD), 
indicating good functionality. The score was low 
in patients with comorbid conditions like chro-
nic obstructive pulmonary disease (COPD) and 
ischemic heart disease (IHD). Anemia was the 
most commonly associated comorbidity. Other 
comorbidities are listed in Table 1.
67 (89%) patients presented with cough as the 
predominant symptom. Only 14 (18.6%) subjects 
complained of minimal expectoration, whereas 53 
(81.4%) had a dry cough. 46 (61%) patients had 
chest pain and 42 (56%) had dyspnea. None of 
the patients presented with hemoptysis. Among 
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Table 1. Demographic profile of the patients
Total number of patients 75
Males 57	(76%)
Females 18	(24%)
Mean	age	at	presentation 36	±	13	(SD)
Mean	BMI 19.58	kg/m2		±	3.88	(SD)
Mean	Karnofsky	score 84	±	10.3	(SD)
Co-morbid	conditions 35	(80.6%)
Anaemia	(haemoglobin	<	10	g/dL) 18	(51.4%)
Chronic	obstructive	pulmonary	
disease
5	(14.2%)
Diabetes	mellitus 2	(5%)
Hypertension 2	(5%)
Ishemic	heart	disease 2	(5%)
Immunocompromised	state 3	(8%)
Cor-pulmonale 2	(5%)
Chronic	liver	disease 1	(2%)
BMI	—	body	mass	index
Table 2. Symptoms at presentation
Symptoms Number of patients
Cough 67	(89%)
Sputum 14	(18.6%)
Dyspnea 42	(56%)
Chest	pain 46	(61%)
Fever 57	(76%)
Loss	of	weight 28	(37%)
Loss	of	appetite 31	(41%)
the constitutional symptoms, fever was the most 
common symptom, seen in 57 (76%) persons. 
31 (41%) and 28 (37%) patients experienced loss 
of appetite and weight, respectively (Table 2).
Light’s criteria were applied to all the pleural 
effusions to determine their nature. The mean pleu-
ral fluid protein and lactate dehydrogenase (LDH) 
was 5.07 g/dL ± 0.82 and 690 U/L ± 316.5, respec-
tively. Median pleural fluid total cell count was 
645 cells/cu.mm (IQR=726). A lymphocyte predo-
minance of ≥70% was seen in 73 patients (97%). 
The mean pleural fluid sugar was 80.5 mg/dL. 
Mean ADA was 61.7 U/L ± 16.2. Pleural fluid CB-
NAAT was positive for MTB in 24 subjects (32%). 
Out of these patients, rifampicin resistance was 
detected in 2 individuals (8.3%). 
Sputum AFB smear was positive in 3 (4%) 
patients, whereas in sputum, CBNAAT MTB was 
detected in 8 (10.6%) subjects. Among them, one 
had rifampicin resistance (Table 3, 4).
Radiological quantification using the afore-
mentioned descriptors revealed mild effusion in 
34 (45.3%) and moderate in 35 (46.6%) people. 
Massive effusion was seen only in 6 (8%) patients. 
Right-sided effusion were predominant and 
was observed in 44 (58.6) patients. 26 (34.6 %) 
subjects had left-sided effusion, whereas 
5 (6.6%) had bilateral effusion. On reviewing 
the chest X-rays for other radiological abnorma-
lities, consolidation was found in 11 (14.7%) 
patients and 2 (2.6%) individuals had miliary 
nodules. 
Table 3.  The mean ± SD values of pleural fluid 
parameters (biochemical and cytology)
Pleural fluid  
parameter
 Mean ± SD
Protein 5	g/dL 0.82
LDH 690	U/L 316.5	
ADA 61.7	U/L 16.2	
%	of	lymphocytes	 95 13.35
ADA	—	adenosine	deaminase;	LDH	—	lactate	dehydrogenase
Table 4.  Pleural fluid and sputum CBNAAT status and 
rifampicin resistance
CBNAAT MTB detected (%) Rifampicin  
resistance (%)
Pleural	fluid 24		(32%) 2	(6%)
Sputum 8	(10.6%) 1	(12.5%)
CBNAAT	—	cartridge-based	nucleic	acid	amplification	test;	MTB	—	Mycobac-
terium tuberculosis
Association between pleural fluid ADA, lym-
phocyte count each individually with CBNAAT 
positivity was evaluated. The mean ADA value in 
the group where CBNAAT was positive for MTB 
was 70.79 ± 15.69, and it was significantly higher 
with a p value of 0.001. In case of CBNAAT po-
sitivity and pleural fluid lymphocyte count, there 
was no significant association (Table 5). 
Discussion
The sensitivity of CBNAAT depends on 
the type of sample on which it is performed. 
Considering the cost and resources involved in 
performing the test, its judicious use lies in the 
hands of the treating physicians. The role of ADA 
in diagnosing TPE has been proved beyond doubt 
and is used as the sole criteria with other bioche-
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 Table 5. Comparison of ADA and lymphocyte count with CBNAAT positivity in pleural fluid 
Variables CBNNAT Total P-value
No Yes
ADA 57.44	±	15.12 70.79	±	15.69 61.83	±	16.46 0.001
LDH 594.69	±	222.47 816.08	±	460.98 667.48	±	334.43 0.007
Lymphocyte	count	(%) 94.94	±	16.53 95.13	±	8.98 95.00	±	14.42 0.959
ADA	—	adenosine	deaminase;	CBNAAT	—	cartridge-based	nucleic	acid	amplification	test;	MTB	—	Mycobacterium tuberculosis
LDH	—	lactate	dehydrogenase
mical and cytological characteristics. Owing to its 
high negative predictive value (NPV) and positive 
predictive value (PPV) in areas of high prevalence, 
it remains a test of great clinical utility. It seldom 
rises beyond 40 U/L in non-tubercular effusions, 
thereby increasing its specificity. That is, ADA 
< 40 excluded tuberculosis in 99% of cases [5]. 
Specificity of ADA in low prevalence areas has also 
been estimated. In a study done in north-western 
Europe, 338 patients with effusions were analyzed, 
and when an ADA cut-off of 35 U/L was used in 
combination with lymphocytic effusions, sensiti-
vity was 90.9% and specificity was 98.9% [6].
In our study, pleural fluid CBNAAT was 
found to be positive in only 32% of cases, and 
rifampicin resistance was seen in 8.3%. In a well-
-structured meta-analysis of 24 studies from India, 
it was seen that the sensitivity of CBNAAT in 
TPE was between 22.7–51.4% using a composite 
reference standard (CRS) and pleural fluid culture 
as the reference standard [2].
In another meta-analysis determining the 
role of genexpert in the diagnosis of extrapul-
monary tuberculosis, a total of 18 studies were 
analyzed with 4461 samples. Pooled sensitivi-
ty for pleural fluid was 46.4% against culture 
and 21.4% against CRS (composite reference 
standards — another NAAT, histology, sme-
ar, biochemical testing, response to ATT) — 
14 studies and 841 samples were included in 
the data. They attributed the poor sensitivity to 
the paucibacillary nature of the disease and the 
presence of polymerase chain reaction (PCR) in-
hibitors in fluid and blood contamination. They 
also suggested that concentration of the pleural 
fluid prior to analysis increased the sensitivity 
[4, 7, 8]. However, in another meta-analysis, 
Meldau et al. compared the diagnostic utility of 
ADA, genexpert and gamma interferon (IFN-g), 
and put forth conflicting findings. They found 
that poor sensitivity of Xpert was neither due to 
sub-optimal detection (requires ≥ 75 CFU/mL) 
compared to other types of biological samples nor 
due to increased PCR inhibition (as there was no 
evidence of PCR inhibition using internal positive 
control). These data confirmed the notion that TPE 
is a paucibacillary disease and concentration of 
fluid for Xpert did not make any difference in im-
proving its sensitivity. They proposed IFN-g to be 
a more sensitive rule in and rule out test than ADA 
in high prevalence settings, and finally, concluded 
that either of the two could be used to guide the-
rapy, as routine pleural biopsy may be challenging 
in high prevalent, resource-limited countries [9]. 
We also studied the association between 
pleural fluid CBNAAT MTB detected, with pleural 
fluid ADA and lymphocyte counts. There was 
a significant connection between CBNAAT positi-
vity and ADA level (p-value = 0.001). In a study 
from India, sensitivity of genexpert in TPE was 
20.58%. Rifampicin resistance was detected in 
21% of cases. They found a positive correlation 
with high ADA values, pleural fluid lymphocyte 
counts and MTB detection by genexpert (r = 0.92, 
r = 0.97, respectively with p < 0.05) [10]. 
In our study, sputum AFB smear was positive 
in 3 (4%) patients, whereas in sputum, CBNAAT 
MTB was detected in 8 (10.6%) individuals. 
Among these 8 patients, MTB was discovered 
by CBNAAT in pleural fluid in 6 (75%), and 
7 (87.5%) had consolidation in their chest X-rays. 
Hence we are of the opinion that patients having 
consolidation along with pleural effusion and 
sputum MTB detected in CBNAAT may have hi-
gher possibility of MTB detection in pleural fluid 
CBNAAT. Similar observation has been made in 
an Indian study done on 106 subjects. They found 
that in patients with pleural effusion with under-
lying lung consolidation, the overall sensitivity 
of PCR for MTB was 92.8% for diagnosing TB 
pleural effusion [11].
Conclusions
Lymphocyte predominant effusions with 
high ADA levels (> 40 U/L) with a compatible 
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clinical presentation, where alternate diagnosis 
seems unlikely are treated as tubercular pleural 
effusions in India. This remains the standard of 
care even to this day. Given the fact that perfor-
ming a pleural biopsy is not feasible at all health 
care centers, and also considering the invasive 
nature of this diagnostic procedure, it is not put 
into routine clinical practice. Sensitivity of ADA 
when combined with lymphocyte predominant 
exudates, in high prevalence areas has stood the 
test of time in deciding the initiation of ATT. Low 
and variable sensitivity of pleural fluid CBNAAT, 
as shown again in our study, should probably 
make us reconsider our decision about performing 
this test routinely (or including it in diagnostic 
protocol). Timely diagnosis of PTB (drug sensitive 
and resistant) is the need of the hour, and we are 
of the honest opinion that the available resources 
have to be channelized in doing the same. We 
suggest that pleural fluid genexpert should be 
performed only when the diagnosis is in doubt 
and can change the patient management. 
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